Alamar Biosciences, Inc. Cost of Revenue
Alamar Biosciences, Inc. (ALMR) reported Cost of Revenue of $11.71 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-11
- Alamar Biosciences, Inc. cost of revenue for the quarter ending 2026-06-30 was $11.71M, a 54.45% increase year-over-year.
- Alamar Biosciences, Inc. cost of revenue for the quarter ending 2026-03-31 was $11.58M, a 72.75% increase year-over-year.
- Alamar Biosciences, Inc. cost of revenue for the quarter ending 2025-06-30 was $7.58M.
- Alamar Biosciences, Inc. cost of revenue for the quarter ending 2025-03-31 was $6.70M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month |
|---|---|---|
| 2026-06-30 | $11.71M 10-Q · filed 2026-08-11 | $23.29M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $11.58M 10-Q · filed 2026-05-08 | |
| 2025-06-30 | $7.58M 10-Q · filed 2026-08-11 | $14.28M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $6.70M 10-Q · filed 2026-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |